Literature DB >> 30377849

Including intangible costs into the cost-of-illness approach: a method refinement illustrated based on the PM2.5 economic burden in China.

Bangzhu Zhu1,2, Runzhi Pang3, Julien Chevallier4,5, Yi-Ming Wei6, Dinh-Tri Vo7,8.   

Abstract

The concentrations of particulate matter with aerodynamic diameters less than 2.5 µm (PM2.5) and 10 µm (PM10) is a widespread concern and has been demonstrated for 103 countries. During the past few years, the exposure-response function (ERf) has been widely used to estimate the health effects of air pollution. However, past studies are either based on the cost-of-illness or the willingness-to-pay approach, and therefore, either do not cover intangible costs or costs due to the absence of work. To address this limitation, a hybrid health effect and economic loss model is developed in this study. This novel approach is applied to a sample of environmental and cost data in China. First, the ERf is used to link PM2.5 concentrations to health endpoints of chronic mortality, acute mortality, respiratory hospital admission, cardiovascular hospital admission, outpatient visits-internal medicine, outpatient visits-pediatrics, asthma attack, acute bronchitis, and chronic bronchitis. Second, the health effect of PM2.5 is monetized into the economic loss. The mean economic loss due to PM2.5 was much heavier in the North than the South of China. Furthermore, the empirical results from 76 cities in China show that the health effects and economic losses were over 4.98 million cases and 382.30 billion-yuan in 2014 and decreased dramatically compared with those in 2013.

Entities:  

Keywords:  Cost-of-illness method; Economic losses; Exposure–response function; Health effects; PM2.5; Willingness-to-pay method

Mesh:

Substances:

Year:  2018        PMID: 30377849     DOI: 10.1007/s10198-018-1012-0

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  2 in total

1.  Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.

Authors:  Frida Schain; Nurgul Batyrbekova; Johan Liwing; Simona Baculea; Thomas Webb; Mats Remberger; Jonas Mattsson
Journal:  Eur J Health Econ       Date:  2020-12-04

2.  REducing delay through edUcation on eXacerbations for people with chronic lung disease: Study protocol of a single-arm pre-post study.

Authors:  Xiaoyue Song; Cynthia Hallensleben; Hongxia Shen; Weihong Zhang; Robbert J J Gobbens; Niels H Chavannes; Anke Versluis
Journal:  J Adv Nurs       Date:  2022-05-27       Impact factor: 3.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.